Latest news

• Biogen triumphs over Mylan’s Tecfidera patent challenge

  The challenge from Mylan focused on Biogen’s ‘514 patent on Tecfidera (dimethyl fumarate) , which is due to expire in 2028. ... Biogen does, however, have its own next-generation MS treatment – Vumerity (diroximel fumarate) – which was recently

• Biogen under fire over $88,000 Vumerity annual price

  Biogen and partner Alkermes scored FDA approval for Vumerity (diroximel fumarate) on the 30 October for the treatment of relapsing forms of MS. ... In comparison, Biogen’s older oral MS drug Tecfidera (dimethyl fumarate) entered the market with a price

• Biogen’s R&D chief Ehlers heads for the exit

  improved tolerability profile –  Vumerity (diroximel fumarate) – is differentiated enough to compensate as Tecfidera sales stall.

• J&J’s ponesimiod tops Aubagio in head-to-head MS trial

  Also coming through the pipeline is Biogen’s Tecfidera follow-up diroximel fumarate (BIIB098), Novartis’ new antibody ofatumumab, and Celgene’s S1P receptor modulator ozanimod that is due for regulatory decision

• Merck takes evobrutinib for MS into phase 3, on mixed data

  If successful, Merck will have a chance to bring forward a new-mechanism therapy for relapsing MS that will compete with blockbuster oral drugs such as Biogen’s Tecfidera (dimethyl fumarate), ... It will also have to contend with newer drugs like